Rezdiffra (Resmetirom) vs Actos (Pioglitazone): Switching Between Them

Why These Two Drugs Get Compared

Resmetirom and pioglitazone occupy the same clinical niche (pharmacotherapy for biopsy-confirmed MASH) but arrived there through entirely different pathways. Pioglitazone has been recommended in AASLD guidance since 2012 for non-diabetic and diabetic patients with biopsy-proven NASH, despite never receiving an FDA indication for the disease [1]. Resmetirom earned its approval in March 2024, becoming the first drug with a specific MASH indication [2].

Clinicians comparing these two agents face a familiar problem: no randomized head-to-head trial. MAESTRO-NASH enrolled adults with biopsy-confirmed MASH and fibrosis stages F1b through F3, while PIVENS enrolled non-diabetic patients with NASH and no cirrhosis [1][2]. The populations differ. The primary endpoints differ. The biopsy scoring methods evolved between 2010 and 2024. Any cross-trial comparison requires those caveats upfront.

Still, the comparison matters. A patient who starts pioglitazone and gains 5 kg may want to switch. A patient who cannot afford resmetirom's list price may need a pioglitazone bridge. Understanding how each drug works, what it does to the liver, and how to transition between them safely is practical, not theoretical.

Mechanism of Action: Two Different Targets in the Same Liver

Resmetirom selectively activates the thyroid hormone receptor beta (THR-beta), which is concentrated in hepatocytes. THR-beta activation increases mitochondrial fatty acid oxidation, reduces hepatic lipogenesis, and lowers circulating LDL cholesterol by upregulating LDL-receptor expression [2]. The drug does not activate THR-alpha, so it avoids the cardiac and bone effects of systemic thyroid hormone excess.

Pioglitazone works through PPAR-gamma, a nuclear receptor expressed primarily in adipose tissue. By improving adipose insulin sensitivity, pioglitazone redirects free fatty acids away from the liver and into peripheral fat stores [3]. It also reduces hepatic and systemic inflammation through effects on macrophage polarization. The trade-off is predictable: better insulin sensitivity comes with expanded adipose mass, fluid retention, and weight gain.

The mechanisms are complementary rather than redundant. Resmetirom burns hepatic fat from the inside out. Pioglitazone redirects fat away from the liver from the outside in. This distinction matters for switching decisions, because a patient who fails one mechanism may respond to the other.

MAESTRO-NASH: The Resmetirom Key Trial

MAESTRO-NASH (N=966) randomized adults with biopsy-confirmed MASH and stage F1b-F3 fibrosis to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks [2]. The dual primary endpoints were NASH resolution with no worsening of fibrosis, and fibrosis improvement by at least one stage with no worsening of the NAFLD Activity Score (NAS).

Results at week 52: NASH resolution occurred in 25.9% of the 80 mg group and 29.9% of the 100 mg group, compared with 9.7% on placebo (P<0.001 for both) [2]. Fibrosis improvement of at least one stage occurred in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% for placebo (P<0.001 for 100 mg).

LDL cholesterol dropped by roughly 16% in the 100 mg arm, a secondary benefit that no other MASH therapy offers. The most common adverse events were diarrhea (27% vs 19% placebo) and nausea (22% vs 14% placebo), both mostly mild and concentrated in the first 12 weeks [2].

PIVENS: The Pioglitazone Landmark

PIVENS (N=247) randomized non-diabetic adults with NASH to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks [1]. The primary endpoint was a composite improvement in the NAS by at least 2 points, with at least 1 point from ballooning and no worsening of fibrosis.

Pioglitazone did not meet the primary endpoint (34% vs 19% placebo, P=0.04 against a pre-specified significance threshold of P=0.025) [1]. It did meet the pre-specified secondary endpoint of NASH resolution: 47% versus 21% for placebo (P<0.001). This 47% figure is frequently cited but deserves context. The trial used a 96-week endpoint, nearly double MAESTRO-NASH's 52 weeks. Longer exposure to any effective agent increases the proportion of responders.

Fibrosis improvement was not statistically significant in PIVENS [1]. Mean weight gain in the pioglitazone arm was 4.7 kg over 96 weeks, and some patients experienced peripheral edema.

Cross-Trial Comparison: What the Numbers Do and Do Not Show

Stacking 29.9% (resmetirom 100 mg at 52 weeks) against 47% (pioglitazone at 96 weeks) without adjustment is misleading. The populations were different: PIVENS excluded patients with diabetes, while MAESTRO-NASH included them. The biopsy time points differ by nearly a year. The histological scoring systems evolved between 2010 and 2024.

What can be said reliably: both drugs reduce NASH activity. Resmetirom has proven fibrosis benefit; pioglitazone does not. Resmetirom lowers LDL; pioglitazone raises HDL and lowers triglycerides but does not reliably reduce LDL. Pioglitazone causes weight gain; resmetirom does not.

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance lists pioglitazone as a pharmacotherapy option for biopsy-proven NASH regardless of diabetes status, and notes resmetirom's conditional approval for MASH with F2-F3 fibrosis [4]. Neither drug is recommended for MASLD without biopsy confirmation of steatohepatitis.

Side-Effect Profiles That Drive Switching Decisions

The most common reason a patient switches from pioglitazone to resmetirom is weight gain. In PIVENS, the 4.7 kg mean gain at 96 weeks underestimates individual variability; some patients gained over 10 kg [1]. Peripheral edema, though usually mild, can be distressing. Long-term pioglitazone use has also been associated with a small increase in fracture risk, particularly in postmenopausal women, based on data from the PROactive trial [5].

Resmetirom's side-effect profile centers on gastrointestinal symptoms: diarrhea and nausea, which tend to be self-limiting. Thyroid function requires monitoring. Resmetirom suppresses TSH in a dose-dependent fashion, which is expected pharmacology rather than toxicity, but clinicians must distinguish drug-induced TSH suppression from true hyperthyroidism [2]. Gallbladder-related events occurred in 3.5% of patients on resmetirom 100 mg versus 0.8% on placebo in MAESTRO-NASH [2].

A switch from resmetirom to pioglitazone is less common but may be driven by gastrointestinal intolerance, gallbladder events, or cost. Generic pioglitazone at under $30 per month removes the financial barrier that resmetirom's approximately $47,400 annual list price creates for many patients.

How to Switch: Practical Clinical Guidance

No published protocol governs switching between resmetirom and pioglitazone. The drugs have no known pharmacokinetic interaction. Resmetirom is metabolized primarily by CYP2C8 and CYP3A4 [2]. Pioglitazone is metabolized by CYP2C8 and CYP3A4 as well [3], which raises a theoretical concern about competitive inhibition during overlap, but clinical drug-interaction studies with resmetirom have not flagged pioglitazone specifically.

Switching from pioglitazone to resmetirom: Pioglitazone can be stopped and resmetirom started the next day. There is no pharmacological reason for a washout period. The insulin-sensitizing effects of pioglitazone persist for several weeks after discontinuation due to the drug's long half-life (16 to 24 hours for pioglitazone, but 3 to 7 days for its active metabolites) [3]. Monitor fasting glucose in diabetic patients during the transition, as insulin sensitivity may decline over the following 4 to 8 weeks.

Switching from resmetirom to pioglitazone: Resmetirom has a half-life of approximately 40 to 50 hours [2]. Starting pioglitazone the day after stopping resmetirom is reasonable. Check TSH 6 to 8 weeks after stopping resmetirom to confirm thyroid axis recovery.

Overlap (combination use): No trial has studied resmetirom plus pioglitazone. Given their complementary mechanisms, combination therapy is a logical hypothesis, but without safety or efficacy data, simultaneous use remains off-protocol. The shared CYP2C8 metabolism warrants caution; if a clinician does prescribe both, monitoring liver enzymes at weeks 4, 8, and 12 is prudent.

Dr. Rohit Loomba, director of the MASLD Research Center at UC San Diego, has noted: "We are entering an era where sequencing and combining MASH therapies will become standard, similar to how we manage hepatitis C today. But we need the trial data to support specific combinations" [6].

Fibrosis: The Outcome That Matters Most

Liver fibrosis stage is the strongest predictor of liver-related mortality and all-cause mortality in MASLD [7]. A drug that resolves steatohepatitis but does not improve fibrosis may reduce inflammation without changing long-term outcomes.

Resmetirom demonstrated statistically significant fibrosis improvement in MAESTRO-NASH: 25.9% of patients on the 100 mg dose achieved at least one stage of fibrosis improvement versus 14.2% on placebo (P<0.001) [2]. This is the basis for the FDA's accelerated approval, which is conditioned on confirmatory outcomes data from the ongoing MAESTRO-OUTCOMES trial.

Pioglitazone did not significantly improve fibrosis in PIVENS (P=0.12) [1]. A separate trial in diabetic patients by Cusi et al. (N=101 to 18 months) did show fibrosis improvement with pioglitazone 45 mg (58% improved by at least one stage vs 27% placebo, P=0.008) [8], but the higher dose and smaller sample size make generalization uncertain. The AASLD guidance acknowledges pioglitazone's inconsistent fibrosis data [4].

For patients with F2 or F3 fibrosis, where the risk of progression to cirrhosis is real and measurable, resmetirom's fibrosis benefit provides a clinical rationale for choosing it first or switching to it from pioglitazone.

Cost, Access, and Insurance Realities

Generic pioglitazone is one of the cheapest oral diabetes medications available: $10 to $30 per month at most pharmacies, often covered without prior authorization [3]. Resmetirom (Rezdiffra) launched at a wholesale acquisition cost of approximately $47,400 per year [2]. Insurance coverage remains inconsistent as of mid-2026. Many commercial payers require biopsy-confirmed MASH with F2-F3 fibrosis, prior liver elastography showing stiffness above 8 kPa, and documentation that lifestyle modifications were attempted.

This cost gap creates a practical sequencing pattern: pioglitazone as a first-line bridge while resmetirom access is being arranged, or pioglitazone as the long-term option for patients whose insurance will not cover resmetirom. The reverse also occurs. A patient who achieves NASH resolution on resmetirom may transition to pioglitazone for maintenance if they cannot sustain the cost.

AASLD guidance from 2023 states: "Cost and access should be considered when selecting pharmacotherapy for NASH, as adherence depends on sustained access to the chosen agent" [4].

Who Should Get Which Drug First

Patient selection depends on fibrosis stage, metabolic profile, and practical constraints. For a non-diabetic patient with F1 fibrosis and elevated ALT, pioglitazone at 30 mg daily remains a reasonable, evidence-based starting point. For a patient with F2 or F3 fibrosis, where fibrosis regression is the primary goal, resmetirom's demonstrated fibrosis benefit and FDA indication make it the preferred first choice if access is achievable.

Patients with concomitant type 2 diabetes may benefit from pioglitazone's insulin-sensitizing effects beyond the liver. For those same patients, if LDL cholesterol is elevated and fibrosis is advancing, resmetirom addresses both concerns simultaneously.

Body weight is a deciding factor for many patients. Pioglitazone's mean 4.7 kg weight gain is unacceptable to some, particularly those already on GLP-1 receptor agonists who are working to lose weight. Resmetirom's weight neutrality avoids that conflict.

Monitoring During and After a Switch

Regardless of direction, any drug switch for MASH should include baseline and follow-up labs. Check ALT, AST, GGT, lipid panel, fasting glucose, HbA1c (if diabetic), and TSH before the switch. Repeat labs at 12 weeks. If the patient was on resmetirom, a dedicated TSH at 6 to 8 weeks after discontinuation confirms thyroid axis recovery.

Imaging follow-up with vibration-controlled transient elastography (FibroScan) or MRI-PDFF at 6 to 12 months after the switch provides a non-invasive readout of hepatic fat and stiffness changes. Repeat biopsy is not required for routine clinical switches but may be warranted if fibrosis progression is suspected.

Weight and peripheral edema should be tracked monthly for the first 3 months after starting pioglitazone. Patients with a history of heart failure (NYHA class III-IV) should not receive pioglitazone [3].